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Abstract
Cost-utility analyses undertaken to inform decision making regarding colorectal cancer (CRC) require a set of health
state utility values (HSUVs) so that the time CRC patients spend in different health states can be aggregated into
quality-adjusted life-years (QALY). This study reviews CRC-related HSUVs that could be used in economic evaluation
and assesses their advantages and disadvantages with respect to valuation methods used and CRC clinical pathways.
Fifty-seven potentially relevant studies were identified which collectively report 321 CRC-related HSUVs. HSUVs (even for
similar health states) vary markedly and this adds to the uncertainty regarding estimates of cost-effectiveness. There are
relatively few methodologically robust HSUVs that can be directly used in economic evaluations concerned with CRC.
There is considerable scope to develop new HSUVs which improve on those currently available either by expanded
collection of generic measures or by making greater use of condition-specific data, for example, using
mapping algorithms.
Keywords: Health state utility value, Colorectal cancer, QALY, Economic evaluation
Abbreviations: AE, Adverse event; CRC, Colorectal cancer; EGFR, Epidermal growth factor receptor;
EORTC, European Organisation for Research and Treatment of Cancer; FACT-G, Functional assessment of
cancer therapy-general; FACT-C, Functional assessment of cancer therapy-cancer; HRQoL, Health-related quality
of life; HSUV, Health state utility value; mCRC, Metastatic colorectal cancer; PBM, Preference-based measure;
QLQ, Quality of life questionnaire; QALY, Quality-adjusted life-year; Q-TWiST, Quality-adjusted time without
symptoms or toxicity; NICE, National Institute for Health and Care Excellence; SG, Standard gamble; TTO, Time
trade-off; TWiST, Time without symptoms or toxicity; UK, United Kingdom; US, United States
Introduction
Colorectal cancer (CRC) is the third most commonly di-
agnosed cancer worldwide [1]. CRC was traditionally
more common in the western world but some Asian
countries have shown an increase in CRC incidence in
recent years [2]. Economic evaluation to inform decision
making regarding CRC requires a set of health state util-
ity values (HSUVs) so that the time CRC patients spend
in different health states can be aggregated into quality-
adjusted life-years (QALYs).
There are four ways by which the required HSUVs can
be empirically generated:
(1)There are generic preference-based measures (PBM),
such as the EQ-5D, SF-6D, 15D and the HUI3, where
generic health states are valued using a tariff based on
the preferences of the general public elicited using
methods such as the time trade-off (TTO) and the
standard gamble (SG).
(2)An alternative approach is to identify a number of
relevant cancer-specific health states (as opposed to
using generic health state descriptions) and to value
these health states directly, again using methods such
as the TTO and the SG. In this case the valuations are
potentially made by cancer patients themselves, health
care professionals or the general public.
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(3)A variation on this second approach is to develop a
preference-based algorithm with which a full range
of cancer-specific health states can be valued. Two
such measures, the EORTC-8D and the QLU-
C10D, are based on items from the Quality of
Life Questionnaire C30 (QLQ-C30).
(4)Finally, a mapping algorithm can be used to transform
cancer-specific data such as the EORTC QLQ-C30
and the Functional Assessment of Cancer Therapy-
General (FACT-G) into generic PBMs.
This paper reviews CRC-related HSUVs that could be
used in economic evaluations and assesses their advan-
tages and disadvantages with reference to the valuation
methods used and CRC clinical pathways.
Review
Methods
The literature was searched to identify CRC-related
HSUVs for use in economic evaluation. MEDLINE,
MEDLINE In-Process & Other Non-Indexed Citations,
Embase (up to 30 October 2015) and Health Economic
Evaluations Database (HEED, up to December 2014)
were searched using the keywords colorectal cancer,
health-related quality of life, QALY and economic evalu-
ation. The search was restricted to studies in English.
The search was broadened to include the National Insti-
tute for Health and Care Excellence (NICE) website
(www.nice.org.uk) to minimise the chance of missing
relevant studies. Economic filters were used when
searching for evidence on generalist databases, such as
MEDLINE. A simplified search was undertaken without
using economic filters, for evidence on economics data-
bases such as HEED. A further search was run on non-
economic databases, including MEDLINE, to capture
studies that are relevant to mapping. Search strategies
are reported in Appendix 1. Relevant conference ab-
stracts were tracked for full journal publications.
All search results were downloaded into EndNote
and duplicates removed. Titles and abstracts were
screened between two independent reviewers and full
papers that did not meet the inclusion criteria were
excluded. The study selection criteria are reported in Ap-
pendix 2. Studies were included if they contained CRC-
related HSUVs which had not been previously reported,
be they generic PBMs or directly valued CRC-related
health state descriptions, or mapping to generic PBMs
based on direct statistical association mapping.
Full text was acquired for the remaining studies
(including those which had insufficient details, such as
no abstract). All included studies were read and any
disagreements were resolved by discussion between the
two reviewers. Of the 285 papers identified as potentially
relevant 228 were excluded because they did not
report CRC-related HSUVs but presented psychomet-
ric validation studies without internal validation proper-
ties, the values were previously reported in other included
studies, they involved unspecified or not clearly specified
CRC-related health state utility values, or a primary map-
ping function was not reported.
A total of 57 studies were included in the reviews (see
Additional file 1). The numerical summary of the search
and selection process for the review is reported in Fig. 1.
Descriptive characteristics (year of publication, country
of origin, intervention type, number and mean age of re-
spondents) and methodological characteristics (what was
the measure of value; how was the health state described
and valued; who valued it; how the QALY was aggre-
gated) were collected for the 57 studies [3]. Findings
from selected studies are discussed in the following
section.
Results
Of the 57 studies, eleven were set in the US [4–14],
eight in the UK [15–22], seven in the Netherlands
[23–29], five in Hong Kong [30–34], four in Canada
[35–38], two each in Norway, Korea, Australia and
Japan [39–46] and other country settings included
Spain, Germany, India, Malaysia, Singapore, Sweden and
Turkey [47–54]. Some studies did not report their
settings or were multinational or multicentre studies
[55–60]. Studies were mostly published in the last
15–20 years and focussed narrowly on different inter-
ventions at specific stages of CRC. For example, the
adverse events (AEs) of chemotherapy and survival
(partial response) in metastatic CRC (mCRC) were the
main condition of interest in several studies [14, 20, 36,
38, 44, 48–50, 56, 58, 59]. HSUVs associated with rectal
cancer have been reported [7, 18, 23–25, 27, 52, 54].
The 57 studies included in this review reported a total
of 368 CRC-related HSUVs. All reported HSUVs are
summarised in Additional file 2.
Generic preference-based measures
Thirty-two studies collected health state information
from CRC patients using generic PBMs, and have
applied health state tariffs based on the preferences of
the general public. These studies generally collect data
from patients recruited to trials, usually several hundred
patients and at multiple time points. The most widely
reported generic PBM is the EQ-5D valued using the
UK (TTO-derived) value set with some exceptions
[28, 57, 58] followed by the SF-6D [6, 30, 33, 34, 37]
and HUI3 [10, 11, 38].
Direct valuation of CRC health states
Fourteen studies directly valued CRC health states.
Preferences have been elicited either using the TTO
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method with patients or a surrogate group [4, 5, 36, 44,
45, 48–50] or SG [7, 8, 13, 20, 35]. Generally, these stud-
ies have involved fewer than 100 respondents. The par-
ticipants have been drawn from CRC patients, health
care professionals and the community or general popu-
lation (non-patient, non-health care professional). Only
one study recruited a sample entirely from the general
population [44] and one entirely from CRC patients [8].
Mean utility values from health care professionals were
lower than those from patients across health states [8, 12].
The remission health state was valued similarly by both
groups, whereas the community group assigned lower
values to adjuvant therapy-related AEs [4].
Preference-based condition-specific measures
Another approach has recently been developed which
offers an alternative to using directly valued health states
from the literature. The EORTC-8D is a cancer-specific
PBM derived from the EORTC QLQ-C30 [61]. It utilises
ten items from the thirty items of the QLQ-C30. A total
of 85 EORTC-8D health states were valued by 350 mem-
bers of the UK general public and these responses were
then modelled to let any of the EORTC-8D states be
valued. The QLU-C10D utilises twelve QLQ-C30 items
to produce a ten dimensional measure [62]. However, to
date this approach has not been used to value CRC
health states.
Mapping
The absence of data on generic PBMs from most cancer
trials has generated considerable interest in mapping
algorithms, from cancer-specific measures such as the
Functional Assessment of Cancer Therapy-General
(FACT-G) and the EORTC QLQ-C30 to measures such
as the EQ-5D and the SF-6D [63, 64]. While several
studies have reported mapping algorithms in the cancer
Fig. 1 Numerical summary of the searches for the review
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area [9, 30, 32, 37, 41, 42, 47], only one of the mapping
algorithms was developed using responses from CRC pa-
tients [65] and only one study has reported HSUVs for
different CRC-related health states based on an algo-
rithm [31]. The mapping studies are summarised in
Additional file 3.
HSUVs and the clinical pathway
For the purposes of estimating QALYs it is usually ne-
cessary to have information on HSUVs at several points
along the clinical pathway. Evaluations of screening or
diagnosis require valuations at the time of the interven-
tion and subsequently following treatment.
CRC Screening-related HSUVs Only one study has re-
ported CRC-screening related HSUVs as presented in
Table 1 [26].
Colostomy-related HSUVs Sixteen colostomy-related
HSUVs were reported from 4 studies [5, 8, 12, 35]. Dis-
utility of 0.09 [8] and of 0.111 [12, 35] were reported
among rectal cancer patients with colostomy compared
with those without colostomy respectively. The utility of
having a stoma among former CRC patients with a re-
versed colostomy was 0.20 lower compared with those
currently have a stoma [12]. HSUVs related to having a
colostomy (surgery) and no colostomy (radiotherapy)
were measured using SG in the primary treatment for
rectal cancer. People with a colostomy assigned a higher
value than people without a colostomy [35]. The sum-
mary of colostomy-related HSUVs is presented in
Table 2.
HSUVs and colorectal polyps Wong and colleagues
[30] reported two HSUVs using SF-6D for those individ-
uals with low- and high-risk colorectal polyps (0.871 and
0.832 respectively).
HSUVs and rectal cancer HSUVs for hypothetical
health states related to therapy for locally recurrent rec-
tal cancer were higher among rectal cancer patients than
health care professionals when measured using SG [7].
Two sets of rectal cancer-related HSUVs were re-
ported at different time points and at different levels of
surgery using EQ-5D and TTO values assigned by the
UK general public [66, 67]. However, no standard devi-
ation of mean values was reported. Overall improved
survival outweighed the disutility related to AEs of
preoperative radiotherapy compared with surgery alone
[18, 27]. A summary of rectal cancer-related HSUVs is
presented in Table 3.
HSUVs and AEs/treatments of CRC Best et al. [4] elic-
ited preferences for seven health states associated with
stage III colon cancer and adjuvant chemotherapy using
TTO among CRC patients and community members.
The TTO values for mCRC obtained from CRC patients
were higher than those obtained from the community
members. Several CRC health states were measured
among CRC patients in Finland and were valued using
the UK TTO tariff [51].
Skin toxicity is a common AE related to epidermal
growth factor receptor (EGFR) agents. Improved HSUVs
related to an EGFR were demonstrated using HUI3
among mCRC patients when compared with best support-
ive care. Health-related quality of life (HRQL) was mea-
sured in mCRC patients and valued by the public [37].
Table 1 CRC screening- related HSUVs
Valuation methods
used
HSUVs reported Reference
EQ-5D Negative FS after positive FIT 0.81
Positive FS after positive FIT 0.82
Kapidzic [26]
COL colonoscopy, CRC colorectal cancer, FIT faecal immunochemical test,
FS flexible sigmoidoscopy, HSUVs health state utility values
Table 2 Colostomy-related HSUVs
Valuation methods
used
HSUVs reported Reference
SG With colostomy 0.915
Without colostomy 0.804
Boyda [35]
TTO [20 years with CRC; 20 years with
a colostomy]
Unscreened [0.80; 0.80]
Screened [0.80; 0.75]
Enrolled in a COL screening
program [0.85; 0.79]
CRC patients [0.83; 0.90]
Dominitz [5]
EQ-5D With stoma 0.836
Without stoma 0.870
Hamashima [40]
SF-6D With stoma 0.69
Without stoma 0.73
Hornbrook [6]
SG Stage II/III rectal cancer,
permanent colostomy 0.50
Stage IV metastatic/unresectable
disease without colostomy 0.25
State IV metastatic/unresectable
disease with colostomy 0.25
Ness [8]
TTO Currently with colostomy 0.84
Reversed colostomy 0.64
Community members 0.63
Smith [12]
EQ-5D PRT and TME PS 0.823
TME PS 0.853
van den Brink
[27]
SG Stage II/III RC treated with
resection, chemotherapy,
radiation therapy and with
permanent ostomy 0.50
Ness [8]
a Reported HSUVs are re-expressed on a 0–1 scale
COL colonoscopy, CRC colorectal cancer, HSUVs health state utility values;
RC rectal cancer, SG standard gamble, TTO time trade-off, PRT preoperative
radiotherapy, TME total mesorectal excision, PS permanent stoma
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Skin toxicity associated with mCRC treatments was re-
ported to have little impact on HRQoL among mCRC
patients [56, 58]. HSUVs obtained from patients with
or without anti-EGFR treatment were applied to the
duration of the AEs (days with grade 3 or higher
AEs) and time without symptoms or toxicity
(TWiST), and the differences were measured using a
quality-adjusted time without symptoms of disease
or toxicity of treatment (Q-TWiST) analysis [60].
Q-TWiST analysis was used to estimate utility values
for three health states among CRC patients with liver
metastasis undergoing hepatic resection [29].
HRQoL measured directly from patients is not always
possible in mCRC; so around 30 carers were used a
number of times as a proxy because terminally ill mCRC
patients would have difficulties in understanding SG or
TTO techniques [20, 36, 48–50]. A summary of HSUVs
associated with CRC treatments and AEs are presented
in Table 4.
Ness et al. [8] reported much lower HSUVs for mCRC
than did other studies [10, 11]. People who previously
underwent the removal of colorectal adenomas assigned
a much lower value to mCRC of 0.25 [8] compared to
CRC survivors 0.81 [10] and 0.85 [11]. CRC patients
assigned relatively higher values to mCRC (0.820) and
palliative care (0.643) compared to those who had no
history of previous or current CRC [51]. Stable and
progressive disease states were given a much higher
value using SG by people who had colorectal adenomas
removed [8] compared with those with CRC using
TTO [4].
Of five studies reporting HSUVs of different CRC stages
HSUVs were clustered ranging from 0.732–0.87 with an
exception of one study 0.25–0.74 [8, 10, 11, 22, 33]. A
summary of selected HSUVs in different CRC stages is
presented in Table 5.
Discussion
There is no shortage of HSUVs available for those wish-
ing to estimate the cost-effectiveness of diagnostic and
treatment strategies with respect to CRC. Those asses-
sing cost-effectiveness face a number of challenges: first,
justifying their selection of values when there is no set
of values that are clearly superior to all others, and sec-
ond, negotiating trade-offs between the advantages and
disadvantages of the available values.
This choice can be simplified where there is an agreed
hierarchy regarding the appropriateness of different ap-
proaches to generating HSUVs. In order to aid resource
allocation and decision making within a tax-funded
healthcare system, economic evaluation needs population
values for specific health states related to CRC. The pref-
erences of the public are generally deemed appropriate
when health services are largely paid for by taxpayers
[59]. Some agencies when have a preference for generic
PBMs being used to report the experience of patients in
the trial from which the effectiveness of the treatment is
being estimated when deciding whether or not to rec-
ommend a new treatment, or in the absence of such
data similar measures reported in the literature would
be used [68].
Researchers usually confront a series of trade-offs and
must make judgements about the importance of having
all HSUVs used in an economic evaluation come from
the same source, or at least obtaining all the HSUVs
using the same methods. The number of HSUVs re-
quired will in part depend on where in the clinical path-
way the intervention being assessed is located. The
earlier in the pathway, the larger the number of poten-
tially relevant health states and the less likely it is that
all the required HSUVs can come from a single study.
Even with clear preferences over the type of measure
and the source of values the decision over which values
to use can be challenging since the ranking of methods
or sources might change in particular circumstances. For
example, trial data is not always to be preferred to obser-
vational data if the latter provide much larger numbers
of observations and are more representative of patients
in routine clinical practice. Also a directly collected gen-
eric PBM might not always be preferred to the same
measure obtained through mapping, for example, if the
latter allowed the valuation of a wider range of CRC-
related health states. It is uncertain if HSUVs related to
mCRC valued by CRC survivors are more relevant than
those by health care professionals when making deci-
sions. Also whether or not HSUVs for mCRC valued by
early CRC patients are more reliable than those valued
Table 3 Rectal cancer-related HSUVs
Valuation methods
used
HSUVs reported Reference
SG Healthcare professionals; patients
Disease recurrence 0.69; 0.72
Surgical resection 0.69; 0.83
Pain and complications 0.50;
0.78
Miller [7]
EQ-5D PRT + TME 0.70-0.86
Recurrent 0.67 (local) 0.70 (distant)
0.48 (local/distant)
TME 0.63-1.0
Recurrent 0.80 (local) 0.64 (distant)
0.45 (local/distant)
Van den Brink
[27]a
EQ-5D Mean EQ-5D (SD)
Baseline before TME 0.88 (0.15)
6 weeks after TME 0.85(0.18)
12 weeks after TME 0.87 (0.19)
26 weeks after TME 0.88 (0.17)
52 weeks after TME 0.86 (0.6)
Hompes [18]
a Ranges of reported HSUVs
HSUVs health state utility values, SD standard deviation, SG standard gamble,
PRT preoperative radiotherapy, TME total mesorectal excision
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by patients with different types of metastatic cancer, has
received little attention.
HSUVs have been measured by a surrogate group such
as oncology nurses, pharmacists or other health care
professionals [20, 36, 48–50]. Despite limitations to the
study design (such as small sample size or under-
explored uncertainties) these HSUVs continue to be
used in economic evaluation studies associated with
CRC [20]. Subsequently, these uncertainties are inherited
by the estimation of cost-effectiveness and of QALYs.
Well-designed clinical studies continue to generate new
evidence that is highly focussed on treatment effects
with strong internal validity. Economic evaluation would
be strengthened if health state data could be taken from
the clinical studies that provide the estimates of effect-
iveness of treatment [69]. Further research which utilises
data from patient-reported outcomes, population surveys,
and cancer registry data in assessing HRQoL and HSUVs
is recommended [70].
Table 4 HSUVs associated with CRC treatments and AEs
Reference Valuation
methods used
HSUVs
Bennett [56] EQ-5D 1st line
Panitimumab + FOLFOX4 0.778;
FOLFOX4 0.756
2nd line
Panitimumab + FOLFIRI 0.769;
FOLFIRI 0.762
Best [4] TTO CRC patients/community
members
Remission 0.83/0.82
adjuvant, no neuropathy 0.61/0.60
adjuvant, mild neuropathy 0.61/0.51
adjuvant, moderate neuropathy 0.53/0.46
adjuvant, severe neuropathy 0.48/0.34
metastatic, stable 0.40)/0.51
metastatic, progressive 0.37/0.21
Dranitsaris [48]b TTO FOLFOX + ‘new drug’→ FOLFIRI→ BSC
until death [2–33 months] 0.68-0.89
FOLFOX→ FOLFIRI→ BSC until death
[2–32 months] 0.70-0.94
Dranitsaris [36]b TTO FOLFOX±’new drug’→ FOLFIRI→ BSC
until death [2–29 months] 0.67-0.83
FOLFOX→ FOLFIRI→ BSC until death
[2–32 months] 0.72-0.91
Dranitsaris [48]b TTO FOLFOX + ‘new drug’→ FOLFIRI→ BSC
until death [2–29 months] 0.52-0.84
FOLFOX→ FOLFIRI→ BSC until death
[2–32 months] 0.53-0.84
Dranitsaris [36]b TTO FOLFOX + ‘new drug’→ FOLFIRI→ BSC
until death [2–28 months] 0.44-0.72
FOLFOX→ FOLFIRI→ BSC until death
[2–32 months] 0.44-0.71
Farkkila [51] EQ-5D Metastatic disease 0.820
Palliative care 0.643
Mittmann [38]b HUI3 Cetuximab + BSC 0.71-0.77
BSC 0.66-0.71
Odom [58] EQ-5D Panitumumab plus BSC; BSC alone
Overall 0.72; 0.68
Wild-type KRAS 0.73; 0.68
Mutant KRAS 0.71; 0.68
Petrou [20]a SG Partial response 1.0
Stable disease 0.95
Progressive disease 0.575
Terminal disease 0.1
Shiroiwa [44] TTO XELOX without AEs 0.59
FOLFOX without AEs 0.53
Febrile neutropenia 0.39
Nausea/vomiting 0.38
Diarrhoea 0.42
Hand-foot syndrome 0.39
Fatigue 0.45
Peripheral neuropathy 0.45
Stomatitis 0.42
Wang [60] EQ-5D Panitumumab + BSC; BSC
TOX 0.6008; 0.4409
TWiST 0.7678; 0.6630
REL 0.6318; 0.6407
Wiering [29] EQ-5D Disease-free 0.78
non-curative 0.67
recurrence 0.74
recurrence with chemotherapy 0.82
Recurrent without chemotherapy 0.68
Table 4 HSUVs associated with CRC treatments and AEs
(Continued)
Ward [14] EQ-VAS Capecitabine and bevacizumab
Baseline 61.76 (SD 23.15)
Cycle 2 68.59 (SD 22.26) [p = 0.06]
End of study 66.54 (SD 23.18) [p = 0.29]
aReported HSUVs are re-expressed on a 0–1 scale
bRanges of reported HSUVs
AE adverse event, BSC best supportive care, FOLFOX Oxaliplatin + infusional 5
fluorouracil (5-FU), FOLFIRI Irinotecan + infusional 5 fluorouracil (5-FU), FOLFOX4
5-fluorouracil/folic acid and oxaliplatin, HSUVs health state utility values, KRAS
Kirsten rat sarcoma viral oncogene, REL (relapse period until death or end of
follow-up), SD standard deviation, SG Standard gamble, TOX days with ≥ grade
3 adverse events, TTO time trade-off, TWiST time without symptoms or toxicity,
XELOX capecitabine plus oxaliplatin
Table 5 HSUVs in CRC
Valuation methods used Reported HSUVs Reference
SG Stage I 0.74
Stage II 0.74 (0.59a)
Stage III 0.67 (0.59a)
Stage IV 0.25
Ness [8]
HUI3 Stage I 0.84
Stage II 0.86
Stage III 0.85
Stage IV 0.84
Ramsey [10]
HUI3 Stage I 0.83
Stage II 0.86
Stage III 0.87
Stage IV 0.81
Ramsey [10]
EQ-5D Dukes stage A + B 0.786b
Dukes stage C + D 0.806b
Wilson [22]a
Mapping from FACT-C to SF-6D Stage I 0.831
Stage II 0.858
Stage III 0.817
Stage IV 0.732
Wong [30]
aRectal cancer; SG Standard gamble
bRe-expressed on a 0–1 scale
FACT-C functional assessment of cancer therapy-cancer
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Given the absence of generic PBM data from many
trials, existing mapping algorithms could be more fully
utilised as an additional means of deriving HSUVs for
economic evaluation of CRC, and also exploratory stud-
ies to derive HSUVs for colorectal cancer health states
from EORTC QLQ-C30 data using the EORTC-8D or
QLU-C10D are warranted.
Although there are a number of algorithms for map-
ping from cancer-specific scales to generic PBMs this
approach has not been frequently reported with respect
to CRC. Cancer-specific scales, such as the QLQ-C30,
capture a number of clinical and domain-specific effects
that might not be captured when using generic PBMs
[68]. Mapping also has the advantage of producing
QALYs measured using a familiar metric. However, any
mapping inevitably introduces additional uncertainty
to the QALY calculation and the cost-effectiveness
estimation.
Important questions associated with HSUVs for the
economic evaluation of CRC remain unanswered. What
is the most accurate way of measuring and valuing
HRQoL in CRC? Is it better to collect HRQoL data dir-
ectly from a small number of CRC patients over a
follow-up period [27]? The studies reviewed gave limited
consideration to the best way to measure and value CRC
health states.
This review highlights gaps in the evidence and op-
portunities for informative research. The most appro-
priate way to measure and value CRC-related health
states should be studied. Developing a set of criteria
for selecting the most appropriate HSUVs that fits the
analyst’s purpose is encouraged. It is not known
whether the mCRC-related HRQoL of CRC survivors
is more representative than those derived from a
small surrogate group. Also, whether mCRC-related
HSUVs valued by early CRC patients are more appro-
priate than those valued by patients with different
types of metastatic cancer for economic evaluation
has been under-researched.
Conclusions
CRC-related HSUVs vary markedly between studies and
across methods. Despite the number of HSUVs pub-
lished, there is not a set of HSUVs that are methodo-
logically robust with a full range of values for health
states of interest appropriate for the use in economic
evaluation of CRC. There is considerable scope for new
HSUVs to be developed which improve on those cur-
rently available and consequently to produce better
estimates of QALYs and cost-effectiveness in order to
better inform resource allocation and healthcare decision
making. In addition, the use of existing mapping algo-
rithms to derive CRC-related HSUVs should be further
explored.
Appendix 1. Search strategies
Appendix 1.1 Search strategy for MEDLINE
Database: Ovid MEDLINE(R), Ovid MEDLINE(R) In-
Process & Other Non-Indexed Citations, Ovid
MEDLINE(R) Daily and Ovid OLDMEDLINE(R)
<1946 to Present>
Platform used: OvidSP.
Date run: 30 October 2015
Search Strategy:
1. Economics/or exp "Costs and Cost Analysis"/or
exp Economics, Hospital/or exp Economics,
Medical/or Economics, Nursing/or Economics,
Pharmaceutical/or Budgets/or exp Models,
Economic/or Markov Chains/or Monte Carlo
Method/or Decision Trees/
2. (econom$ or cba or cea or cua or markov$ or
(monte adj carlo) or (decision adj2 (tree$ or
analys$)) or (cost or costs or costing$ or costly or
costed) or (price$ or pricing$) or budget$ or
expenditure$ or (value adj2 (money or monetary))
or (pharmacoeconomic$ or (pharmaco adj
economic$))).ti,ab.
3. 1 or 2
4. "Value of Life"/
5. Quality-Adjusted Life Years/
6. quality adjusted life year.tw.
7. (qaly$ or qald$ or qale$ or qtime$).tw.
8. disability adjusted life.tw.
9. daly$.tw.
10. Health Status Indicators/
11. (sf36 or sf 36 or short form 36 or shortform 36 or
sf thirtysix or sf thirty six or shortform thirtysix
or shortform thirty six or short form thirtysix
or short form thirty six).tw.
12. (sf6 or sf 6 or short form 6 or shortform 6 or sf six
or sfsix or shortform six or short form six).tw.
13. (sf12 or sf 12 or short form 12 or shortform 12 or
sf twelve or sftwelve or shortform twelve or short
form twelve).tw.
14. (sf16 or sf 16 or short form 16 or shortform 16 or
sf sixteen or sfsixteen or shortform sixteen or
short form sixteen).tw.
15. (sf20 or sf 20 or short form 20 or shortform 20 or
sf twenty or sftwenty or shortform twenty or short
form twenty).tw.
16. (euroqol or euro qol or eq5d or eq 5d).tw.
17. (qol or hql or hqol or hrqol).tw.
18. (hye or hyes).tw.
19. health$ year$ equivalent$.tw.
20. utilit$.tw.
21. (hui or hui$1 or hui$2 or hui$3).tw.
22. disutili$.tw.
23. rosser.tw.
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24. quality of wellbeing.tw.
25. quality of well-being.tw.
26. qwb.tw.
27. willingness to pay.tw.
28. standard gamble$.tw.
29. time trade off.tw.
30. time tradeoff.tw.
31. tto.tw.
32. mapping.tw.
33. mapped.tw.
34. crosswalk.tw.
35. transfer$ to utilit$.tw.
36. or/4–35
37. ((colorectal or colon$ or rectal or rectum$) and
(cancer$ or tumor$ or tumor$ or neoplasm$ or
carcinoma$ or adenoma$)).tw.
38. Colorectal Neoplasms/or Colonic Neoplasms/or
rectal neoplasms/
39. crc.tw.
40. 37 or 38 or 39
41. 36 and 40
42. 3 and 41
43. limit 42 to humans
Appendix 1.2 Search strategy for mapping
studies - MEDLINE
Database: Ovid MEDLINE(R) In-Process & Other
Non-Indexed Citations, Ovid MEDLINE(R) Daily, Ovid
MEDLINE(R) and Ovid OLDMEDLINE(R) <1946 to
Present>
Platform used: OvidSP. Date run: 30 October 2015
Search Strategy:
1. ((colorectal or colon$ or rectal or rectum$) and
(cancer$ or tumor$ or tumor$ or neoplasm$ or
carcinoma$ or adenoma$)).tw.
2. Colorectal Neoplasms/or Colonic Neoplasms/or
rectal neoplasms/
3. crc.tw.
4. or/1–3
5. mapping$.tw.
6. mapped$.tw.
7. (crosswalk$ or cross walk$).tw.
8. transfer$ to utilit$.tw.
9. (euroqol or euro qol or eq5d or eq 5d).tw.
10. (sf36 or sf 36 or short form 36 or shortform 36 or
sf thirtysix or sf36 or shortform thirtysix or
shortform 36 or short form thirtysix or short
form 36).tw.
11. (sf6 or sf 6 or short form 6 or shortform 6 or sf six
or sfsix or shortform six or short form six).tw.
12. (sf12 or sf 12 or short form 12 or shortform 12 or
sf 12 or sftwelve or shortform 12 or short form
12).tw.
13. (sf16 or sf 16 or short form 16 or shortform 16 or
sf 16 or sfsixteen or shortform 16 or short form
16).tw.
14. (sf20 or sf 20 or short form 20 or shortform 20 or
sf 20 or sftwenty or shortform 20 or short form
20).tw.
15. or/5–14
16. 4 and 15
17. limit 16 to humans
18. remove duplicates from 17
Appendix 2. Study selection criteria
Studies were excluded if;
 the title/abstract were irrelevant to HRQoL or
CRC-related HSUVs
 conference abstracts with no full publication
 Psychometric validation studies or description of
health states without interval properties rather
than valuation of health states
 values were previously reported in other included
studies
 unspecified/not clearly specified health states
relating to CRC
 primary mapping function is not reported in studies
Studies were included if;
 CRC-related HSUVs which were had not been
reported previously which were
○ preference-based generic measure such as
EQ-5D, HUI3, and SF-6D
○ or directly valued health state descriptions
○ or mapping to generic preference-based
measures based on direct statistical association
mapping
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